Sabinsa announces five new patents

Sabinsa announces five new patents pertaining to digestive health, sports nutrition, heart health, and sexual health.

Sabinsa Corp. (East Windsor, NJ) announced five new patents. Two patents pertained to Sabinsa’s LactoSpore ingredient. The first patent (US10792295) claims that the combination of Lactospore with β-glucogallin (Saberry) inhibits the growth of Helicobacter pylori. The second patent (US10806760) claims LactoSpore can reduce flatulence formed by fermentation of food microbes when the probiotic and prebiotic fibers are cultured along with gas producing microbes. The patent also claims a method for inhibiting the growth of gas-producing microbes such as E. coli, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter johnsonii, Methanobrevibacter smithii, Bilophila wadsworthia, and Clostridium difficile.

The third patent granted to Sabinsa (US10716823) is for the company’s endurance composition comprised of boswellic acids-polysaccharides derived from Boswellia serrata (Boswellin PS) in combination with either the concentrate of the liquid endosperm of Cocos nucifera, or the extract of Emblica officinalis fruit standardized to contain at least 10% w/w of 1-O-galloyl-β-D-glucose (β-glucogallin). According to the patent, the adaptogenic composition increases endurance capacity under sustained physical activity, and protects against hypoxic injury, modifies biochemical parameters, and increases neuromuscular co-ordination in subjects exposed to amplified physical stress.

In its fourth patent (US10864243), Sabinsa claims that its composition of extracts of Allium sativum, Beta vulgaris, Nigella sativa, and Terminalia arjuna is effective in inhibiting Prostaglandin transporter (PGT). PGT is transmembrane protein involved in the transport of prostaglandins (PG) into the cell. Uptake of PGs into the cells may lead to clinical conditions such as hypertension and cardiovascular complications, making PGT a new target for drug development.

The final patent (US10864242) supports the use of a formula consisting of Withania somnifera, Mucuna pruriens, Coleus forskohlii, and Kaempferia parviflora extracts, along with bioavailability enhancer BioPerine, to manage male sexual dysfunction. According to the patent, the composition effectively reduces symptoms such as erectile dysfunction, premature ejaculation, delayed or inhibited ejaculation, and reduced libido, by modifying different biochemical markers and pathways.

“Patenting our discoveries is an important part of protecting the investments our customers make when they formulate with our ingredients,” said Sabinsa Founder and Chairman Muhammed Majeed, PhD, in a press release. “Innovation drives the industry, and more importantly provides additional ways to contribute to the health of humanity.”